Biotech and healthcare dominate this year’s VC-backed IPOs
Square’s widely anticipated IPO has captured a great deal of attention this week, but it’s biotech companies that should be getting the top billing.
19 November 2015•1 min read
Square’s widely anticipated IPO has captured a great deal of attention this week, but it’s biotech companies that should be getting the top billing.
